Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

COVID-19

ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Ivermectin

Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Placebo

Stromectol. FDA Approved Package Insert 2009

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

The subject is considered to have progressed to severe illness when one or more of the following criteria are present:
Breathing difficulty (≥30 breaths per minute);
Resting oxygen saturation ≤93%;
Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.

Japanese Encephalitis

IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.
Placebo group received 0.9% saline intravenous at similar rate.

Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]

Kanti Children's Hospital

BP Koirala Institute of Health Sciences

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal

Patients will be monitored for side effects such as infusion site reaction, diarrhea, rise in blood pressure (in mm Hg) and change in urinary output (in ml/Kg/hour) every 12 hours from first day of commencing treatment until until death or discharge. Patient on average are administered the study drug on the first day of admission. The study drug is administered daily for 5 days. Patients are discharged on an average on eighth day (192 hours) of hospital admission.

At the time of discharge(expected average of eighth day of admission) or death: Time to death, to recover from coma, to sit independently, to stand independently, to walk at least 5m independently, and to leave hospital.
At 6 months after discharge: history of further seizures, behavioral changes, evidence of recovery of neurological sequelae such as assessment of ability to sit independently, to stand independently, to walk at least 5 meters independently.

Pre-treatment was immediately prior to the first dose of study drug on the first day, mid-treatment was immediately prior to the 4th dose and post-treatment was 1hour after administering the fifth dose of the study drug.

Ajit Rayamajhi

Clinical Research Fellow (PhD Student)

University of Liverpool

B.P. Koirala Institute of Health Sciences

West Nile Fever

VRC-WNVDNA020-00-VP

National Institutes of Health Clinical Center, 9000 Rockville Pike

Phase I Study of West Nile Virus Vaccine

A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects

National Institute of Allergy and Infectious Diseases (NIAID)

Drug: 17D YF Vaccine plus Ig; one vaccine on day 0

Viremia

YF-VAX® plus saline

17D YF Vaccine plus Ig, one vaccine on day 0

17D YF Vaccine plus Ig,

Emory Vaccine Center-The Hope Clinic and The Pediatric ID Clinic

Yellow Fever Virus Vaccine and Immune Globulin Study

Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D)

yellow fever/céphalée

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Phase I Study of West Nile Virus Vaccine

Yellow Fever Virus Vaccine and Immune Globulin Study

La base de données d'herbes médicinales la plus complète soutenue par la science